Structure Therapeutics Inc ADR(GPCR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:10 PM ET (Korea 10/29 05:10)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.08 | Insider Own | 2.6% | Shs Outstand | 71.2M | Perf Week | -2.41% |
| Market Cap | 1.53B | Forward P/E | - | EPS next Y | -28.83% | Insider Trans | - | Shs Float | 69.5M | Perf Month | -34.29% |
| Enterprise Value | 0.20B | PEG | - | EPS next Q | -0.33 | Inst Own | 90.2% | Short Float | 10.29% | Perf Quarter | -56.58% |
| Income | -0.22B | P/S | - | EPS this Y | -108.19% | Inst Trans | 1.15% | Short Ratio | 6.69 | Perf Half Y | -48.07% |
| Sales | 0.00B | P/B | 1.13 | EPS next 5Y | - | ROA | -19.2% | Short Interest | 7.15M | Perf YTD | -69.12% |
| Book/sh | 19.02 | P/C | 1.14 | EPS past 3/5Y | -18.36% -40.35% | ROE | -20.24% | 52W High | -77.37% ($94.90) | Perf Year | -25.8% |
| Cash/sh | 18.83 | P/FCF | - | Sales past 3/5Y | - | ROIC | -15.84% | 52W Low | 3.64% ($20.73) | Perf 3Y | -68.49% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 1.47% | Gross Margin | - | Volatility(W/M) | 4.99% 6.13% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.52 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 20.75 | EPS Q/Q | -36.11% | Profit Margin | - | RSI (14) | 23.25 | Recom | 1.12 |
| Dividend Gr. 3/5Y | - | Current Ratio | 20.75 | Sales Q/Q | - | SMA20 | -9.58% ($23.76) | Beta | -1.32 | Target Price | $106.73 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/6 | SMA50 | -38.02% ($34.66) | Rel Volume | 0.92 | Prev Close | $21.55 |
| Employees | 220 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -11.8% - | SMA200 | -56.74% ($49.65) | Avg Volume(3M) | 1.07M | Price | $21.48 |
| IPO | 2023/2/3 | Option/Short | Yes/Yes | Trades | 6933 | Volume | 986,369 | Change | -0.32% |
🧬 A clinical-stage biotech company developing obesity and metabolic disease therapeutics. It develops oral treatments for obesity and metabolic disorders and is gaining attention for its clinical progress. The company is a biotech firm focused on obesity and metabolic disease therapeutics.
Over the past 1 year, on the lower side
77% below its 1-year high.
Traded about as much as usual. That is 92% of its average volume.
GPCR has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -108.2% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -68.5%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 90.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #126 of 594 in the industry
Based on market cap of $2B.
GPCR#126 Structure Therapeutics Inc ADR $2B PER - 
INVA#127 Innoviva Inc $2B PER 5.2 
REPL#128 Replimune Group Inc $2B PER - 
ANAB#129 AnaptysBio Inc $2B PER 7.8 
TYRA#130 Tyra Biosciences Inc $1B PER - 
FAQ
What kind of company is GPCR?
GPCR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GPCR?
The market cap of GPCR is approximately $1.5B, ranking 2,288 within its sector.
What is the 52-week high and low for GPCR?
GPCR has recorded a 52-week high of $94.90 and a low of $20.73.
